30
2020-12
Kintor Pharmaceutical Won the Award of Futu Annual Best Investor Relations Hong Kong-listed Company
Suzhou, Dec. 29, 2020----真人直营投注网站 (HKEX:9939) is pleased to announce that the company won the Award of the Best Investor Relations Hong Kong-listed Company in the 2020 Annual Review of the Community of Futubull held by Futu recently, which was also the first time for the company to win this award.
20
2020-12
Kintor Pharma's shares have been included in FTSE Index
Suzhou, Dec. 20, 2020--真人直营投注网站 is pleased to announce that the company‘s shares have been included in FTSE Global Equity Index Series micro-cap index, with effective after the close of business on December 18.
11
2020-12
Preliminary Results from the Proxalutamide's COVID-19 Trial
Suzhou, Dec. 11, 2020--真人直营投注网站 (HKEX: 9939) is pleased to update the preliminary analysis of the Clinical Trial of Proxalutamide for the treatment of COVID-19.
09
2020-12
Kintor to Present Results of GT90001 and Opdivo Combo Study at 2021 ASCO GI
On December 9, 2020, Kintor has announced to present results of GT90001 and Opdivo combo study at 2021 ASCO GI.
25
2020-11
Female Subjects Included in Clinical Trial of Proxalutamide Treating COVID-19
真人直营投注网站 announced that the clinical trial of Proxalutamide in the treatment of COVID-19 was based on the positive results preliminarily shown in the treatment of male subjects.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn